Pharmaceuticals, Biotechnology, & Life Sciences

Companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. Includes companies specializing in protein-based therapeutics to treat human diseases. Excludes companies manufacturing products using biotechnology but without a health care application.

Companies engaged in the research, development or production of pharmaceuticals. Includes veterinary drugs.

Companies enabling the drug discovery, development and production continuum by providing analytical tools, instruments, consumables & supplies, clinical trial services and contract research services. Includes firms primarily servicing the pharmaceutical
and biotechnology industries.

Profit & Loss

$ 2021 2020 2019 2018 2017
Revenue 10,310,000,000 9,150,800,000 8,538,600,000 7,915,300,000 6,922,800,000
Cost of Goods Sold -4,466,700,000 -3,924,400,000 -3,761,200,000 -3,531,600,000 -3,326,800,000
Gross Profit 5,843,300,000 5,226,400,000 4,777,400,000 4,383,700,000 3,596,000,000
Operating Costs -2,713,300,000 -2,509,900,000 -2,273,400,000 -2,003,400,000 -1,827,100,000
Operating Profit 3,130,000,000 2,716,500,000 2,504,000,000 2,380,300,000 1,768,900,000
Financing Costs -166,900,000 -143,800,000 -162,900,000 -99,100,000 -79,100,000
Profit Before Tax 2,963,100,000 2,572,700,000 2,341,100,000 2,281,200,000 1,689,800,000
Income Tax -588,100,000 -470,200,000 -422,400,000 -552,300,000 -352,400,000
Profit 2,375,000,000 2,102,500,000 1,918,700,000 1,728,900,000 1,337,400,000

Balance Sheet

$ 2021 2020 2019 2018 2017
Current Assets 7,389,700,000 6,446,200,000 5,540,100,000 4,993,700,000 4,602,100,000
Non-Current Assets 10,767,200,000 9,018,500,000 6,774,300,000 5,780,800,000 4,520,600,000
Total Assets 18,156,900,000 15,464,700,000 12,314,400,000 10,774,500,000 9,122,700,000
Current Liabilities 3,103,600,000 2,141,500,000 2,188,200,000 1,914,700,000 1,618,100,000
Non-Current Liabilities 6,672,000,000 6,795,700,000 4,874,900,000 4,779,900,000 4,340,800,000
Total Liabilities 9,775,600,000 8,937,200,000 7,063,100,000 6,694,600,000 5,958,900,000
Total Equity 8,381,300,000 6,527,500,000 5,251,300,000 4,079,900,000 3,163,800,000

Cash Flow

$ 2021 2020 2019 2018 2017
Cash Flow from Operating Activities 3,621,900,000 2,488,300,000 1,644,400,000 1,902,100,000 1,246,600,000
Cash Flow from Investing Activities -1,673,200,000 -1,366,700,000 -1,287,300,000 -1,534,100,000 -862,900,000
Cash Flow from Financing Activities -1,401,800,000 -642,700,000 -491,500,000 -371,500,000 -103,500,000
Net Change in Cash 546,900,000 478,900,000 -134,400,000 -3,500,000 280,200,000
Cash at Beginning 1,151,300,000 657,800,000 812,700,000 843,000,000 555,300,000
Exchange Fluctuations 31,900,000 14,600,000 -20,500,000 -26,800,000 7,500,000
Cash at End of Period 1,730,100,000 1,151,300,000 657,800,000 812,700,000 843,000,000

Profitability

  2021 2020 2019 2018 2017
Gross Margin 56.7% 57.1% 56.0% 55.4% 51.9%
Operating Margin 30.4% 29.7% 29.3% 30.1% 25.6%
Profit Margin 23.0% 23.0% 22.5% 21.8% 19.3%

Management Effectiveness

  2021 2020 2019 2018 2017
Return on Assets 13.1% 13.6% 15.6% 16.0% 14.7%
Return on Equity 28.3% 32.2% 36.5% 42.4% 42.3%
Current Ratio 2.38 3.01 2.53 2.61 2.84
Debt to Equity Ratio 1.17 1.37 1.35 1.64 1.88

Valuation

  2021 2020 2019 2018 2017
Share Price ($) 285.19 287.00 215.00 192.62 138.03
Shares on Issue 455,128,517 454,048,707 453,138,632 452,400,784 453,454,237
Market Capitalisation ($) 129,798,101,763 130,311,978,909 97,424,805,880 87,141,439,014 62,590,288,333
Revenue per Share ($) 22.65 20.15 18.84 17.50 15.27
Earnings per Share ($) 5.22 4.63 4.23 3.82 2.95
Dividends per Share ($) 2.10 1.94 1.78 1.49 1.33
Dividend Yield 0.7% 0.7% 0.8% 0.8% 1.0%
Price to Sales Ratio 12.6 14.2 11.4 11.0 9.0
Price to Earnings Ratio 54.7 62.0 50.8 50.4 46.8
Price to Book Ratio 15.5 20.0 18.6 21.4 19.8

All Companies in the Pharmaceuticals, Biotechnology, & Life Sciences Group

Alphabetic by Name